TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services
|| Print ||
|Monday, 09 November 2009 15:00 (UTC + 1)|
Delft, the Netherlands, November 09, 2009 / b3c newswire / - Today, TNO, a Dutch contract research organization, and Seventh Wave, an American organization for contract research and consultancy, announce that the companies have signed a letter of intent with regard to TNO’s dynamic in vitro gastrointestinal models “TIM”. The letter of intent proposes a collaboration in which Seventh Wave will obtain two TIM systems for commercialization in North America. The TIM systems will be used to determine the behavior of oral drug products and drug substances during passage through the gastrointestinal tract.
According to the terms stated in the letter of intent, TNO will supply its proprietary gastrointestinal models to Seventh Wave Laboratories, located in Chesterfield, Missouri. This central U.S. location, coupled with Seventh Wave’s customer responsiveness, will shorten study turnaround time for customers in North America. The TIM system has been validated for use in preclinical drug development. Both parties expect the TIM systems to be installed and ready for use by customers in the first quarter of 2010. In addition to the collaboration on the current models, the partners envisage joint projects to further validate the TIM system for new applications.
John Sagartz, President and CEO of Seventh Wave, adds: “TIM compliments our current preclinical and clinical services. With the TIM system available on site, we have another valuable tool to solve our customers’ specific needs in formulation development and pharmacokinetics.”
TNO gastroIntestinal Model (TIM)
Seventh Wave - www.7thwavelabs.com
Seventh Wave is a consulting and contract research organization providing integrated preclinical ADME/PK, pharmacology, toxicology, pathology, and clinical PK. With a continuous commitment to quality, Seventh Wave operates its consulting and laboratory services as an extension of its clients’ project teams in the design and timely execution of their preclinical development strategies.